Visiongain has launched a new pharma report ‘’Neuroendocrine Carcinoma Market Report 2020-2030’’ by Therapy {Hemotherapy, Radiation Therapy (Radiofrequency Ablation (RFA) and Local Excision), Surgery}, Site (Brain, Gastrointestinal, Lung, Pancreas, Others), Diagnostic Tools {Biopsy, Imaging (CT scan, X-Ray, PET Scan and Others), Serology (Urine Test, Blood Test, Molecular Test, And Others), Others}, and Geography.

The global neuroendocrine carcinoma market is anticipated to grow at a lucrative CAGR of 8.2% and anticipated to reach USD 3.86 Billion by 2030.

A neuroendocrine tumor is a type of tumor that starts with the endocrine system and nervous system in the hormone generating cells of the neuroendocrine system. Neuroendocrine cell-producing hormones have a neuron-like structure and contain hormones like endocrine cells. Such cells are located in organs such as intestines, kidneys, lungs, and stomach throughout the body and perform tasks such as regulating the velocity of food through the gastrointestinal tract and circulating through the lungs by air and blood. Neuroendocrine tumor is a rare malignancy that accounts for almost 1% of all malignant disorders.

Neuroendocrine carcinomas account for almost 60% of all cases of neuroendocrine tumors and are described as their source in various locations throughout the body including lungs, gastrointestinal tract, and brain. Hyperglycemia, hypoglycemia, weight loss, loss of appetite, migraine, nausea, gastric ulcer, irregular bleeding, jaundice, vomiting, fatigue, and persistent particular area are some common symptoms associated with neuroendocrine carcinoma.

Operation, radiation therapy, and chemotherapy are the treatment options for neuroendocrine carcinoma. Chemotherapy includes the use of drugs by inhibiting the capacity of cells to expand and divide to kill cancer cells. Some medicines used to treat neuroendocrine carcinomas are streptozocin (Zanosar) and5-fluorouracil (Adrucil, 5-FU). Continuous attempts by major pharmaceuticals to improve targeted therapy led to the development of the carcinomas market of neuroendocrine. Everolimus (Afinitor) and sunitinib (Sutent) are two major active drugs used to treat carcinomas of neuroendocrine.

Afinitor was approved for the treatment of advanced renal cell carcinoma by Novartis AG in 2009. The medicine is beneficial if renal cell carcinoma is not treated with sunitinib or sorafenib. Sutent is a Pfizer Ltd.-developed product used for the treatment of advanced renal cell carcinoma and gastrointestinal tumor. F. Hoffmann-La Roche Ltd., BioSynthema, Inc., Genentech Inc., Pvt Pharmaceuticals Callisto. Ltd. are some of the major companies that aim to produce drugs to treat various carcinomas of neuroendocrine.

Market segmentation is focused on scanning, biopsy, serology, and other diagnostic tools. The section of serology is also known as urine test, blood test, molecular analysis, and others. The section of visualization is categorized into CT scans, X-rays, PET scans, and others. The growing adoption of advanced diagnostic imaging techniques capable of detecting very tiny, clinically insignificant malignant tumors contributes over the forecast period to the growth of the imaging market.

It is considered the largest market in North America. The rising incidence of NETs in the United States makes this continent the primary investment market and the launch of new products. The United States ranks first in the number of NETs clinical trials worldwide followed by the United Kingdom due to the presence of a large patient population in this field. Approximately 8,000 people are diagnosed with a carcinoid tumor in the UK each year, according to the National Health Service in 2015, and this number is expected to rise over the forecast period.

It shows the potential demand in Europe in the coming years for NETs care. The Asia Pacific neuroendocrine carcinoma market is expected to see lucrative growth as the incidence of NETs in this area rises.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products to strengthen their position in the global neuroendocrine carcinoma market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the Neuroendocrine Carcinoma market.

The comprehensive market report features companies such as AbbVie Inc., Aegis Therapeutics, Amgen Inc., AVEO Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Chiasma Inc., Dauntless Pharmaceuticals, Delcath Systems Inc., Exelixis, Inc., Hutchison MediPharma Limited, Ispen, Jubilant Life Sciences Ltd. (Jubilant DraxImage), Novartis AG, Pfizer, Progenics Pharmaceuticals, Inc., Tarveda Therapeutics among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.